

**AMENDMENT TO RULES COMMITTEE PRINT**

**118-10**

**OFFERED BY MR. DAVIDSON OF OHIO**

At the end of subtitle C of title VII, insert the following new section:

1 **SEC. 7\_\_\_ . STUDY AND REPORT ON HEALTH CONDITIONS**  
2 **OF MEMBERS OF THE ARMED FORCES DE-**  
3 **VELOPED AFTER ADMINISTRATION OF**  
4 **COVID-19 VACCINE.**

5 (a) STUDY.—The Secretary of Defense shall conduct  
6 a study to assess and evaluate any health conditions arising  
7 in members of the Armed Forces after one year after  
8 receiving the first dose of a COVID-19 vaccine, and each  
9 of the two years thereafter.

10 (b) STUDY PARAMETERS.—In conducting the study  
11 under subsection (a), the Secretary shall—

12 (1) disaggregate data collected by—

13 (A) vaccine type and manufacturer;

14 (B) age group at the time such first dose  
15 was administered, including—

16 (i) individuals who have attained 18  
17 years of age but who have not yet attained  
18 30 years of age;

1 (ii) individuals who have attained 30  
2 years of age but who have not yet attained  
3 40 years of age;

4 (iii) individuals who have attained 40  
5 years of age but who have not yet attained  
6 50 years of age;

7 (iv) individuals who have attained 50  
8 years of age but who have not yet attained  
9 60 years of age; and

10 (v) individuals who are 60 years of  
11 age or older; and

12 (C) health condition developed after receiv-  
13 ing such first dose, regardless of whether the  
14 condition is attributable to the receipt of such  
15 first dose; and

16 (2) assess the prevalence of each such health  
17 condition—

18 (A) by each age group specified in para-  
19 graph (1)(B) among the unvaccinated popu-  
20 lation; and

21 (B) among each such age group for each  
22 of the years 2015, 2016, 2017, 2018, and  
23 2019.

24 (c) REPORT.—Not later than one year after the date  
25 of the enactment of this Act and each year thereafter for

1 the subsequent four years, the Secretary shall submit to  
2 the Committees on Armed Services of the House of Rep-  
3 resentatives and the Senate a report on the results of each  
4 study conducted under subsection (a).

5 (d) COVID-19 VACCINE DEFINED.—The term  
6 “COVID-19 vaccine” means a vaccine licensed under sec-  
7 tion 351 of the Public Health Service Act (42 U.S.C. 262)  
8 or authorized for emergency use under section 564 of the  
9 Federal Food, Drug, and Cosmetic Act (21 U.S.C.  
10 360bbb-3) for immunization against the virus responsible  
11 for COVID-19.

